Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: The role of GLUT-4 and endothelin

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 2, 2008, Pages

  Lekli, Istvan ^a   Szabo, Gergo ^a   Juhasz, Bela ^a   Das, Samarjit ^a,b   Das, Manika ^b   Varga, Edit ^a   Szendrei, Levente ^a   Gesztelyi, Rudolf ^a   Varadi, Judit ^a   Bak, Istvan ^a   Das, Dipak K ^b   Tosaki, Arpad ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Diabetes; Heart; Ischemia reperfusion; Rat

Indexed keywords

ENDOTHELIN; ENDOTHELIN 1; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; RESVERATROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA FLOW; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEART VENTRICLE FIBRILLATION; INCIDENCE; INSULIN BLOOD LEVEL; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; ZUCKER RAT;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; BLOOD GLUCOSE; BLOOD PRESSURE; ELECTROCARDIOGRAPHY; ENDOTHELIN-1; GLUCOSE TRANSPORTER TYPE 4; HEART RATE; IN SITU NICK-END LABELING; INSULIN; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; OBESITY; RATS; RATS, ZUCKER; SIGNAL TRANSDUCTION; STILBENES;

EID: 39149137233     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01048.2007     Document Type: Article

References (48)

1. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RA, Murphy MP, Sammut IA. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 19: 1088-1095, 2005.
2. Ahlborg G, Shemyakin A, Bohm F, Gonon A, Pernow J. Dual endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care 30: 591-596, 2007.
3. Allen LA, O'Donnell CJ, Camargo CA Jr, Giugliano RP, Lloyd-Jones DM. Comparison of long-term mortality across the spectrum of acute coronary syndromes. Am Heart J 151: 1065-1071, 2006.
4. Atherton HJ, Bailey NJ, Zhang W, Taylor J, Major H, Shockcor J, Clarke K, Griffin JL. A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolic study of the PPAR-alpha null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol Genomics 27: 178-186, 2006.
5. Bergman RN, Mittelman SD. Central role of the adipocyte in insulin resistance. J Basic Clin Physiol Pharmacol 9: 205-221, 1998.
6. Bjursell M, Ahnmark A, Bohlooly YM, William-Olsson L, Rhedin M, Peng XR, Ploj K, Gerdin AK, Arnerup G, Elmgren A, Berg AL, Oscarsson J, Linden D. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 56: 583-593, 2007.
7. Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 29: 109-117, 2006.
8. Chao HH, Juan SH, Liu JC, Yang HY, Yang E, Cheng TH, Shyu KG. Resveratrol inhibits angiotensin II-induced endothelin-1 gene expression and subsequent proliferation in rat aortic smooth muscle cells. Eur J Pharmacol 515: 1-9, 2005.
9. Clarke JF, Young PW, Yonezawa K, Kasuga M, Holman GD. Inhibition of the translocation of GLUT-1 and GLUT-4 in 3T3-L1 cells by the phosphatidylinositol 3-kinase inhibitor, wortmannin. Biochem J 300: 631-635, 1994.
10. Cross HR, Opie LH, Radda GK, Clarke K. Is a high glycogen content beneficial or detrimental to the ischemic rat heart? A controversy resolved. Circ Res 78: 482-491, 1996.
11. Das S, Tosaki A, Bagchi D, Maulik N, Das DK. Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. J Pharmacol Exp Ther 317: 980-988, 2006.
12. Depre C, Vanoverschelde JLJ, Taegtmeyer H. Glucose for the heart. Circulation 99: 578-588, 1999.
13. Dickson WE, Blehar DJ, Carraway RE, Heard SO, Steinberg G, Przyklenk K. Naloxone blocks transferred preconditioning in isolated rabbit hearts. J Mol Cell Cardiol 33: 1751-1756, 2001.
14. Dresner A, Laurent D, Marucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103: 253-259, 1999.
15. Finck BN, Lehmann JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP. The cardiac phenotype induced PPAR-alpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109: 121-130, 2002.
16. Fremont L, Gozzelino MT, Linard A. Response of plasma lipids to dietary cholesterol and wine polyphenols in rats fed polyunsaturated fat diets. Lipids 35: 991-999, 2000.
17. From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, Rodeheffer RJ, Roger VL. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 119: 591-599, 2006.
18. Gerber HP, McMurtrey A, Kowalsk J, Yan M, Keyt BA, Dixit V, Ferrara N. Vascular endothelial growth factor regulates cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. J Biol Chem 273: 33036-33043, 1998.
19. Goldfine AB, Beckman JA, Betensky RA, Devlin H, Hurley S, Varo N, Schonbeck U, Patti ME, Creager MA. Family history of diabetes is a major determinant of endothelial function. J Am Coll Cardiol 47: 2456-2461, 2006.
20. Greer JJ, Ware DP, Lefer DJ. Myocardial infarction and heart failure in the db/db diabetic mouse. Am J Physiol Heart Circ Physiol 290: H146-H153, 2006.
21. Groop LC. The molecular genetics of non-insulin dependent diabetes mellitus. J Intern Med 241: 95-110, 1997.
22. Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension 10: 512-516, 1987.
23. Kaga S, Zhan L, Matsumoto M, Maulik N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J Mol Cell Cardiol 39: 813-822, 2005.
24. Kahn BB. Glucose transport: pivotal step in insulin action. Diabetes 45: 1644-1654, 1996.
25. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Reed JC, Olivett G, Anversa P. Apoptotic and necrotic myocyte cell death are independent contributing variables of infarct size in rats. Lab Invest 74: 86-107, 1996.
26. Kanaya AM, Barrett-Connor E, Wassel Fyr CL. Endothelin-1 and prevalent coronary heart disease in older men and women (the Rancho Bernardo Study). Am J Cardiol 99: 486-490, 2007.
27. Kaplan S, Morgan JA, Bisleri G, Cheema FH, Akman HO, Topkara VK, Oz MC. Effects of resveratrol in storage solution on adhesion molecule expression and nitric oxide synthesis in vein grafts. Ann Thorac Surg 80: 1773-1778, 2005.
28. King LM, Opie LH. Glucose delivery is a major determinant of glucose utilization in the ischemic myocardium with a residual coronary flow. Cardiovasc Res 39: 381-392, 1998.
29. Kluft C, Jesperson J. Diabetes as a procoagulant condition. Br J Diabetes Vasc Dis 2: 358-362, 2002.
30. Liu JC, Chen JJ, Chan P, Cheng CF, Cheng TH. Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol. Hypertension 42: 1198-2005, 2003.
31. Lopaschuk GD. Metabolic abnormalities in the diabetic heart. Heart Fail Rev 7: 149-159, 2002.
32. Maulik N, Yoshida T, Zu YL, Sato M, Banerjee A, Das DK. Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2. Am J Physiol Heart Circ Physiol 275: H1857-H1864, 1998.
33. McTigue K, Larson JC, Valoski A, Burke G, Kotchen J, Lewis CE, Stefanick ML, Van Horn L, Kuller L. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA 296: 79-86, 2006.
34. Miatello R, Vazquez M, Renna N, Cruzado M, Ponce Zumino A, Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 18: 864-870, 2005.
35. Nascimento NR, Lessa LM, Kerntopf MR, Sousa CM, Alves RS, Queiroz MG, Price J, Heimark DB, Larner J, Du X, Brownlee M, Gow A, Davis C, Fonteles MC. Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide. Proc Natl Acad Sci USA 103: 218-223, 2006.
36. Panagia M, Gibbons GF, Radda GK, Clarke K. PPAR-alpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am J Physiol Heart Circ Physiol 288: H2677-H2683, 2005.
37. Sasaki H, Ray PS, Zhu L, Otani H, Asahara T, Maulik N. Hypoxia/reoxygenation promotes myocardial angiogenesis via an NFκB-dependent mechanism in a rat model of chronic myocardial infarction. J Mol Cell Cardiol 33: 283-294, 2001.
38. Schultz JE, Yao Z, Cavero I, Gross GJ. Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart. Am J Physiol Heart Circ Physiol 272: H2607-H2615, 1997.
39. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 51: 1110-1117, 2002.
40. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, Turi ZG, Strauss HW, Willerson JT, Robertson T. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 14: 49-57, 1989.
41. Szolcsanyi J, Oroszi G, Nemeth J, Szilvassy Z, Blasig IE, Tosaki A. Functional and biochemical evidence for capsaicin-induced neural endothelin release in isolated working rat heart. Eur J Pharmacol 419: 215-221, 2001.
42. Tian R, Abel ED. Responses of GLUT 4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation 103: 2961-2966, 2001.
43. Tooke JE, Hannemann MM. Adverse endothelial function and the insulin resistance syndrome. J Intern Med 247: 425-431, 2000.
44. Verma S, Arikawa E, McNeill JH. Long-term endothelin receptor blockade improves cardiovascular function in diabetes. Am J Hypertens 14: 679-687, 2001.
45. Verma S, Maitland A, Weisel RD, Fedak PW, Li SH, Mickle DA, Li RK, Ko L, Rao V. Increased endothelin-1 production in diabetic patients after cardioplegic arrest and reperfusion impairs coronary vascular reactivity: reversal by means of endothelin antagonism. J Thorac Cardiovasc Surg 123: 1114-1119, 2002.
46. Wainwright CL, McCabe C, Kane KA. Endothelin and the ischemic heart. Curr Vasc Pharmacol 3: 333-341, 2005.
47. Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, Jucker BM. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion- induced myocardial injury. Diabetes 54: 554-562, 2005.
48. Zimmet P, Alberti KGMM, Shaw J. Global and social implications of the diabetes epidemic. Nature 414: 782-787, 2001.